Optimizing first-line chemotherapy in metastatic pancreatic cancer: efficacy of folfirinox versus nab-paclitaxel plus gemcitabine

HIGHLIGHTS

SUMMARY

    The estimated median survival from diagnosis without treatment for metastatic (m) PC, based on large case series and national registries, is 3 mos in a the authors study of 32,452 patients and 10 weeks in a Dutch study of 3099 patients, mainly due to the difficulties in the diagnosis for the deteriorated PS at diagnosis and the lack of effective treatments. Carrato et_al reported in a systematic 2 of 11 review that the median OS in patients with metastatic PC in Europe was less than 5 mos and that less than 10% of . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?